A case report of seizure induced by bupropion nasal insufflation [1]

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 9, Issue 1, 2007, Pages 67-69

  Hill, Stanley ^a   Sikand, Harminder ^a   Lee, Jonathan ^a  

^a SCRIPPS MERCY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMFEBUTAMONE; LORAZEPAM; OLANZAPINE;

ADULT; AERATION; ALCOHOL BLOOD LEVEL; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DEPRESSION; DRUG ABUSE; EUPHORIA; HUMAN; LETTER; MALE; SCHIZOAFFECTIVE PSYCHOSIS; SEIZURE; SMOKING;

EID: 33847114935     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/pcc.v09n0114a     Document Type: Letter

References (23)

1. Johnston JA, Lineberry CG, Ascher JA, et al. A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry 1991;52:450-456
2. Dunner DL, Zisook S, Billow AA, et al. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry 1998;59:366-373
3. Pesola GR, Avasarala J. Bupropion seizure proportion among new-onset generalized seizures and drug related seizures presenting to an emergency department. J Emerg Med 2002;22:235-239
4. Shepherd G, Velez LI, Keyes DC. Intentional bupropion overdoses. J Emerg Med 2004;27:147-151
5. Welsh CJ, Doyon S. Seizure induced by insufflation of bupropion [letter]. N Engl J Med 2002;347:951
6. Khurshid KA, Decker DH. Bupropion insufflation in a teenager. J Child Adolesc Psychopharmacol 2004;14:157-158
7. Mehta NB. The chemistry of bupropion. J Clin Psychiatry 1983;44:56-59
8. Preskorn SH, Othmer SC. Evaluation of bupropion hydrochloride: the first of a new class of atypical antidepressants. Pharmacotherapy 1984;4:20-34
9. Ferris RM, White HL, Cooper BR, et al. Some neurochemical properties of a new antidepressant, bupropion hydrochloride (Wellbutrin). Drug Develop Res 1981;1:21-35
10. Cooper BR, Hester TJ, Maxwell RA. Behavioral and biochemical effects of the antidepressant bupropion: evidence for selective blockade of dopamine uptake in vivo. J Pharmacol Exp Ther 1980;215:127-134
11. Griffith JD, Carranza J, Griffith C, et al. Bupropion: clinical assay for amphetamine-like abuse potential. J Clin Psychiatry 1983;44:206-208
12. Del Paggio D. Psychotropic medication abuse in correctional facilities. Bay Area Psychopharmacol Newsletter 2005;8:1-5
13. Erowid. Erowid experience vaults: bupropion. Available at: http://www.erowid.org/experiences/subs/exp_Pharms_-_Bupropion.shtml. Accessed Oct 3, 2005
14. Graff CL, Pollack GM. Nasal drug administration: potential for targeted central nervous system delivery. J Pharm Sci 2005;94:1187-1195
15. Schroeder DH. Metabolism and kinetics of bupropion. J Clin Psychiatry 1983;44:79-81
16. Lai AA, Schroeder DH. Clinical pharmacokinetics of bupropion: a review. J Clin Psychiatry 1983;44:82-84
17. Harris DS, Boxenbaum H, Everhart ET, et al. The bioavailability of intranasal and smoked methamphetamine. Clin Pharmacol Ther 2003;74:475-486
18. Cook CE, Jeffcoat AR, Hill JM, et al. Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. Drug Metab Dispos 1993;21:717-723
19. Butz RF, Schroeder DH, Welch RM, et al. Radioimmunoassay and pharmacokinetic profile of bupropion in the dog. J Pharmacol Exp Ther 1981;217:602-610
20. Goodnick PJ. Pharmacokinetics of second-generation antidepressants: bupropion. Psychopharmacol Bull 1991;27:513-519
21. Preskorn SH. Antidepressant response and plasma concentrations of bupropion. J Clin Psychiatry 1983;44:137-139
22. Davidson J. Seizures and bupropion: a review. J Clin Psychiatry 1989;50:256-261
23. Goodnick PJ. Blood levels and acute response to bupropion. Am J Psychiatry 1992;149:399-400